Use of biologics and other novel therapies for the treatment of systemic sclerosis.
about
Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
P2860
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@en
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@nl
type
label
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@en
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@nl
prefLabel
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@en
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
@nl
P2093
P2860
P1476
Use of biologics and other novel therapies for the treatment of systemic sclerosis
@en
P2093
Armando Gabrielli
Emanuela Praino
Marco Matucci-Cerinic
Oliver Distler
Yannick Allanore
P2860
P304
P356
10.1080/1744666X.2017.1263153
P577
2016-12-12T00:00:00Z